Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41


Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.

Mathieu C, Bode BW, Franek E, Philis-Tsimikas A, Rose L, Graungaard T, Birk Østerskov A, Russell-Jones D.

Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13205. [Epub ahead of print]


Pilot Test of a Culturally Appropriate Diabetes Prevention Intervention for At-Risk Latina Women.

McCurley JL, Fortmann AL, Gutierrez AP, Gonzalez P, Euyoque J, Clark T, Preciado J, Ahmad A, Philis-Tsimikas A, Gallo LC.

Diabetes Educ. 2017 Dec;43(6):631-640. doi: 10.1177/0145721717738020. Epub 2017 Oct 23.


Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.

Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, Nielsen TSS, Warren M; Group Information; SWITCH 1.

JAMA. 2017 Jul 4;318(1):33-44. doi: 10.1001/jama.2017.7115.


Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group.

N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.


Dulce Digital: An mHealth SMS-Based Intervention Improves Glycemic Control in Hispanics With Type 2 Diabetes.

Fortmann AL, Gallo LC, Garcia MI, Taleb M, Euyoque JA, Clark T, Skidmore J, Ruiz M, Dharkar-Surber S, Schultz J, Philis-Tsimikas A.

Diabetes Care. 2017 Oct;40(10):1349-1355. doi: 10.2337/dc17-0230. Epub 2017 Jun 9.


Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).

Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Østerskov AB, Graungaard T, Bergenstal RM.

Diabetes Care. 2017 Jul;40(7):943-950. doi: 10.2337/dc16-1771. Epub 2017 Mar 29.


A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.

King AB, Philis-Tsimikas A, Kilpatrick ES, Langbakke IH, Begtrup K, Vilsbøll T.

Diabetes Technol Ther. 2017 Apr;19(4):255-264. doi: 10.1089/dia.2016.0405. Epub 2017 Mar 10.


REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes.

Aleppo G, Ruedy KJ, Riddlesworth TD, Kruger DF, Peters AL, Hirsch I, Bergenstal RM, Toschi E, Ahmann AJ, Shah VN, Rickels MR, Bode BW, Philis-Tsimikas A, Pop-Busui R, Rodriguez H, Eyth E, Bhargava A, Kollman C, Beck RW; REPLACE-BG Study Group.

Diabetes Care. 2017 Apr;40(4):538-545. doi: 10.2337/dc16-2482. Epub 2017 Feb 16.


Dulce Wireless Tijuana: A Randomized Control Trial Evaluating the Impact of Project Dulce and Short-Term Mobile Technology on Glycemic Control in a Family Medicine Clinic in Northern Mexico.

Anzaldo-Campos MC, Contreras S, Vargas-Ojeda A, Menchaca-Díaz R, Fortmann A, Philis-Tsimikas A.

Diabetes Technol Ther. 2016 Apr;18(4):240-51. doi: 10.1089/dia.2015.0283. Epub 2016 Feb 25.


Novel approach to inpatient glucometric monitoring and variability in a community hospital setting.

Koziol J, Johnson K, Brenner K, Fortmann A, Morrisey R, Philis-Tsimikas A.

J Diabetes Sci Technol. 2015 Mar;9(2):246-56. doi: 10.1177/1932296814564992. Epub 2014 Dec 23.


Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators.

Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1.


Dulce Mothers: an intervention to reduce diabetes and cardiovascular risk in Latinas after gestational diabetes.

Philis-Tsimikas A, Fortmann AL, Dharkar-Surber S, Euyoque JA, Ruiz M, Schultz J, Gallo LC.

Transl Behav Med. 2014 Mar;4(1):18-25. doi: 10.1007/s13142-014-0253-4.


Implementing community-based diabetes programs: the scripps whittier diabetes institute experience.

Philis-Tsimikas A, Gallo LC.

Curr Diab Rep. 2014 Feb;14(2):462. doi: 10.1007/s11892-013-0462-0.


A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action.

Drab SR, Philis-Tsimikas A.

Pharmacotherapy. 2014 Mar;34(3):291-302. doi: 10.1002/phar.1361. Epub 2013 Oct 17. Review.


Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control.

Philis-Tsimikas A.

Am J Med. 2013 Sep;126(9 Suppl 1):S21-7. doi: 10.1016/j.amjmed.2013.06.010. Review.


Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.

Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C; BEGIN Once Long trial investigators.

Diabet Med. 2013 Nov;30(11):1298-304. doi: 10.1111/dme.12303. Epub 2013 Sep 30.


Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use).

Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J.

Adv Ther. 2013 Jun;30(6):607-22. doi: 10.1007/s12325-013-0036-1. Epub 2013 Jun 29.


Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).

Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, Endahl L, Mathieu C; NN1250-3579 (BEGIN Once Long) Trial Investigators.

Diabetes Care. 2012 Dec;35(12):2464-71. doi: 10.2337/dc12-1205. Epub 2012 Oct 5.


Precision, accuracy, and user acceptance of the OneTouch SelectSimple blood glucose monitoring system.

Philis-Tsimikas A, Chang A, Miller L.

J Diabetes Sci Technol. 2011 Nov 1;5(6):1602-9.

Supplemental Content

Loading ...
Support Center